762-763 / 2437
Lynch et al. N Engl J Med 2004
Paez et al. Science 2004
Matsumoto et al. Int J Cancer 2006
Park et al. Lung Cancer 2012
Maemondo et al. N Engl J Med 2010
Rosell et al. Lancet Oncol 2012
• Activating EGFR mutations particularly commmon in
adenocarcinomas of the lung
• EGFR mutations may be overrepresented in brain mets
of lung cancer patients
• Clinical activity of EGFR inhibitors in patients with
activating EGFR mutations has been shown in several
large trials
• Modest BBB penetration of EGFR inhibitors
EGFR inhibitors